Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals (NASDAQ: REGN) took it’s sweet time, but reached the first profit target this week!
Now as a correction forms, I’m watching my market forecasting tools carefully to see how the bulls react.
If they begin to weaken substantially, then I would expect to see price retest last week’s highs and that would be the end of the run for now.
If on the other hand, they continue to accumulate into this pullback by “buying the dip”, than I would expect to see the uptrend continue and would hold fast. So my management choices coming at the end of the seek that is to come will be entirely determined by how the bulls react to this correction.